Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maricruz Anaya-Ruiz

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Asian Pacific Journal of Cancer Prevention : APJCP|May 20, 2015
Innovation status of gene therapy for breast cancerMaricruz Anaya-Ruiz, Martin Perez-Santos
Pharmaceutical Patent Analyst|December 8, 2021
Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatmentMaricruz Anaya-Ruiz, Martin Perez-Santos
Pharmaceutical Patent Analyst|February 16, 2022
Drug repurposing of adapalene for melanoma treatmentMaricruz Anaya-Ruiz, Martin Perez-Santos
Asian Pacific Journal of Cancer Prevention : APJCP|December 3, 2013
Mexican breast cancer research output, 2003-2012Jose Luis Martin Perez-Santos, Maricruz Anaya-Ruiz
Recent Patents on Anti-Cancer Drug Discovery|October 15, 2016
Contribution of Latin American Countries to Cancer Research and Patent Generation: Recent PatentsMartin Perez-Santos, Maricruz Anaya-Ruiz, Cindy Bandala
Asian Pacific Journal of Cancer Prevention : APJCP|November 7, 2014
Cervical cancer trends in Mexico: incidence, mortality and research outputMaricruz Anaya-Ruiz, Ana Karen Vincent, Martin Perez-Santos
Frontiers in Bioinformatics|June 10, 2025
Quality over quantity: how to get the best results when using docking for repurposingLenin Domínguez-Ramírez, Maricruz Anaya-Ruiz, Paulina Cortés-Hernández
Asian Pacific Journal of Cancer Prevention : APJCP|July 27, 2013
miR-485 acts as a tumor suppressor by inhibiting cell growth and migration in breast carcinoma T47D cellsMaricruz Anaya-Ruiz, Cindy Bandala, Jose Luis Martin Perez-Santos
Expert Opinion on Therapeutic Patents|April 17, 2019
Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1Martin Perez-Santos, Maricruz Anaya-Ruiz, Jorge Cebada, et al.
Expert Opinion on Drug Discovery|November 18, 2022
Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agentsMartin Perez-Santos, Maricruz Anaya-Ruiz, Luis Villafaña-Diaz, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Asian Pacific Journal of Cancer Prevention : APJCP|May 20, 2015
Innovation status of gene therapy for breast cancerMaricruz Anaya-Ruiz, Martin Perez-Santos
Pharmaceutical Patent Analyst|December 8, 2021
Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatmentMaricruz Anaya-Ruiz, Martin Perez-Santos
Pharmaceutical Patent Analyst|February 16, 2022
Drug repurposing of adapalene for melanoma treatmentMaricruz Anaya-Ruiz, Martin Perez-Santos
Asian Pacific Journal of Cancer Prevention : APJCP|December 3, 2013
Mexican breast cancer research output, 2003-2012Jose Luis Martin Perez-Santos, Maricruz Anaya-Ruiz
Recent Patents on Anti-Cancer Drug Discovery|October 15, 2016
Contribution of Latin American Countries to Cancer Research and Patent Generation: Recent PatentsMartin Perez-Santos, Maricruz Anaya-Ruiz, Cindy Bandala
Asian Pacific Journal of Cancer Prevention : APJCP|November 7, 2014
Cervical cancer trends in Mexico: incidence, mortality and research outputMaricruz Anaya-Ruiz, Ana Karen Vincent, Martin Perez-Santos
Frontiers in Bioinformatics|June 10, 2025
Quality over quantity: how to get the best results when using docking for repurposingLenin Domínguez-Ramírez, Maricruz Anaya-Ruiz, Paulina Cortés-Hernández
Asian Pacific Journal of Cancer Prevention : APJCP|July 27, 2013
miR-485 acts as a tumor suppressor by inhibiting cell growth and migration in breast carcinoma T47D cellsMaricruz Anaya-Ruiz, Cindy Bandala, Jose Luis Martin Perez-Santos
Expert Opinion on Therapeutic Patents|April 17, 2019
Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1Martin Perez-Santos, Maricruz Anaya-Ruiz, Jorge Cebada, et al.
Expert Opinion on Drug Discovery|November 18, 2022
Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agentsMartin Perez-Santos, Maricruz Anaya-Ruiz, Luis Villafaña-Diaz, et al.
Pageof 4